Shares in Zosano Pharma Corp. (NASDAQ:ZSAN) spiked considerably in the premarket today, after positive study data was confirmed for one of the company’s primary products under development. The results came swiftly, with the study enrollment in November, and concluding at the beginning of January.
ZSAN stock surged as high as 2.28 in premarket trading this morning, and could be gearing up for another bullish run, even after having seen a steady and considerable rise over the past few months. Since November, at the start of the study, shares have come from less than .50, and increase several times over to their current pricing.
The boost has been helped along considerably this morning as Zosano Pharma Corp. (NASDAQ:ZSAN) reported that in its ZOTRIP pivotal efficacy study, the company’s M207 transdermal migraine therapy patch met both primary, as well as secondary endpoints. It bodes well for the future of the treatment as it continues its way through trials.
About Zosano Pharma Corp
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Learn more at www.zosanopharma.com.
About ZP-Triptan and M207
ZP-Triptan is a formulation of zolmitriptan, one of a class of serotonin receptor agonists known as triptans used for the treatment of migraine. ZP-Triptan microneedle patch is applied to an individual’s upper arm to deliver zolmitriptan to the body, with the objective of providing rapid onset relief from headache symptoms. The Company announced positive results from Phase I clinical trial of ZP-Triptan patch, which was conducted in healthy human subjects in Australia.
Zosano Pharma’s investigational migraine treatment, M207, is a novel formulation of zolmitriptan, a drug used orally and nasally to effectively and safely treat migraines, administered via the Company’s proprietary transdermal delivery system. M207 is being investigated as a potential treatment to provide rapid relief of migraine symptoms, at any time in the migraine cycle, in a discreet and simple manner.
M207 Meets Primary and Secondary Endpoints in Pivotal Study
As we mentioned above, this morning, the ruckus on the chart has been catalyzed by the revelation of positive study data on the company’s novel transdermal patch for migraines. The data showed that M207 patients’ results were far superior to the placebo group, and there were no serious adverse reaction events that were recorded throughout the study.
The key highlights of the study data:
- 5% of patients experienced freedom from pain at 2 hours vs. 14.3% for placebo
- 3% of patients experienced freedom from most bothersome symptom at 2 hours vs. 42.9% for placebo
- 8% of patients experienced freedom from pain at 1 hour vs. 10.4% for placebo
Stewart Tepper, MD, Professor of Neurology at Dartmouth and Director of the Dartmouth Headache Clinic commented, “The ZOTRIP study was successful from the dual perspectives of meeting the co-primary endpoints and no serious adverse events. The study demonstrated a statistically significant 2-hour pain freedom response rate with a low placebo rate for the primary endpoint. The data also indicate a durability of effect at 24 and 48 hours, and meaningful pain freedom rate at 1 hour. If approved by the FDA, M207 has the potential to become an important treatment option for those suffering from migraine.” (Source: Globe Newswire)
What will happen to shares of Zosano Pharma Corp. (NASDAQ:ZSAN) once this fresh development is traded upon more heavily to start the week? That remains to be seen, and we will certainly be tracking their movements here at Street Register. Stay locked on StreetRegister.com, add us to your bookmarks, and be sure you’re signed up for our 100% free smallcap newsletter. Simply enter your primary active email address in the box below! Subscribe now!